| Released | Contributor | Author | Title | Pages | Price |
| 9-Feb-2010 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 9-Feb-2010 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 9-Feb-2010 | EconomicInvestor |
N/A
| "The Economy Matters" Report for RPRX: the economy's impact on RPRX's price and risk, featuring the powerful EconomicInvestor Star Rating | 6 |
$15 |
| 8-Feb-2010 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for RPRX | 13 |
$25 |
| 6-Feb-2010 | Pechala's Reports | Frantisek Pechala | REPROS THERAPEUTICS INC (RPRX=US) 12-months forecast | 1 |
$15 |
| 6-Feb-2010 | Standard & Poor's Quantitative Report |
N/A
| Repros Therapeutics | 6 |
$25 |
| 5-Feb-2010 | Pechala's Reports | Lubomir Pechala | REPROS THERAPEUTICS INC (RPRX=US) 2-weeks forecast | 1 |
$10 |
| 4-Feb-2010 | Ford Investor Services, Inc. |
N/A
| Value Graph: REPROS THERAPEUT -- RPRX | 1 |
$4 |
| 4-Feb-2010 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ASTM , AVII , NYMX , RPRX , RXII -- DRUGS | 3 |
$4 |
| 2-Feb-2010 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for Repros Therapeutics Inc. | 41 |
$65 |
1.52% Nasdaq 0.00%
Research Reports
